© 2021 HealthCore Inc.
menu
search
menu
search
keyboard_backspace News & Press Releases

ADA Scientific Sessions 2021

June 25-29, 2021

ADA Virtual 81st Scientific Sessions

ADA’s Virtual 81st Scientific Sessions features discussion from leading diabetes experts on topics ranging from diabetes technology to advances in prevention and patient care. Included is 800 presentations, more than 1,000 poster presentations, and an online poster forum. Registration is required to view presentations. For more information, please visit: professional.diabetes.org.

 

HealthCore Poster Presentations

General Poster Session
Friday, June 25 | 11:30 AM – 12:30 PM ET

649-P | Impact of Early Initiation of Dulaglutide on A1C in Patients with Type 2 Diabetes
Hoog M1, Smith J2, Yu M1, Peleshok J1, Mody R1, Grabner M2
1Eli Lilly and Company, Indianapolis, IN, 2HealthCore, Inc., Wilmington, DE

652-P | Real-world Effectiveness of Once-Weekly Semaglutide (sema OW) From a US Commercially Insured and Medicare Advantage Population
Willey V1, Shivappa N1, Noone J2, Swift C2, Du S1, Paprocki YM2, Tan H1
1HealthCore, Inc., Wilmington, DE, 2Novo Nordisk, Plainsboro Township, NJ

653-P | Evaluating Antidiabetic Medication Treatment Patterns in T2D Patients Initiating Once-Weekly Semaglutide (sema OW)
Willey V1, Shivappa N1, Swift C2, Noone J2, Du S1, Paprocki YM2, Tan H1
1HealthCore, Inc., Wilmington, DE, 2Novo Nordisk, Plainsboro Township, NJ

683-P| Real-World Evaluation of Once-Weekly Semaglutide (sema OW) in Patients Newly Initiating GLP-1 Agonist Therapy
Shivappa N1, Swift C2, Noone J2, Du S1, Paprocki YM2, Tan H1, Willey V1
1HealthCore, Inc., Wilmington, DE, 2Novo Nordisk, Plainsboro Township, NJ

805-P | Risk of Severe Complications of Urinary Tract Infection in Real-World Use of Dapagliflozin
Johannes C1, Layton J1, Beachler DC2, Ziemiecki RM1, Li L2, Danysh HE1, Dinh J2, Hunt PR3, Karlsson C3, Chen H3, Gilsenan A1
1RTI, Research Triangle Park, NC, 2HealthCore, Inc., Wilmington, DE, 3AstraZeneca, Gaithersburg, MD

806-P | Risk of Acute Liver Injury in Real-World Use of Dapagliflozin
Johannes C1, Chen H3, Gilsenan A1, Layton J1, Beachler DC2, Ziemiecki RM1, Li L2, Danysh HE1, Dinh J2, Hunt PR3, Karlsson C3
1RTI, Research Triangle Park, NC, 2HealthCore, Inc., Wilmington, DE, 3AstraZeneca, Gaithersburg, MD

1271-P | Real-World Effectiveness of Newly Initiated Once-Weekly Semaglutide (sema OW) by Prescriber Specialty
Shivappa N1, Noone J2, Swift C2, Du S1, Tan H1, Paprocki YM2, Willey V1
1HealthCore, Inc., Wilmington, DE, 2Novo Nordisk, Plainsboro Township, NJ

Late Breaking Poster Session
Friday, June 25 | 11:30 AM – 12:30 PM ET

50-LB | Using Cluster Analysis to Identify Attitudes towards Diabetes-Related Technology
Eby EL1, Stephenson JJ2, Gelsey F1, Poon J1, Governor SB2, Nguyen C2, Willey V2
1Eli Lilly and Company, Indianapolis, IN, 2HealthCore, Inc., Wilmington, DE

86-LB| Real-World Effectiveness of Oral Semaglutide (OS) from a US Commercially Insured and Medicare Advantage Population
Shivappa N1, Swift C2, Noone J2, Du S1, Radin M2, Gamble C2, Tan H1, Willey V1
1HealthCore, Inc., Wilmington, DE, 2Novo Nordisk, Plainsboro Township, NJ

 

Oral Presentation

Friday, June 25 | 4:15 PM – 6:15 PM ET

14-OR | Risk of Acute Kidney Injury in Real-World Use of Dapagliflozin
Johannes C1, Layton J1, Beachler DC2, Ziemiecki RM1, Li L2, Danysh HE1, Dinh J2, Hunt PR3, Karlsson C3, Chen H3, Gilsenan A1
1RTI, Research Triangle Park, NC, 2HealthCore, Inc., Wilmington, DE, 3AstraZeneca, Gaithersburg, MD

 

*HealthCore authors are indicated in bold.